Related Tags >> Phase II FDA Exelixis Biotech company news

adverse events News

Most Popular adverse events Story

FDA more friendly to approvable than approved

January 10, 2008 — 7:59am ET

You've probably already heard that FDA approvals took a nasty dive last year, with analysts... Read more...

adverse events Press Releases

PRESS RELEASE: Adverse Drug Events Reported to FDA Appear to Have Increased Markedly

Latest Headlines

Safety oversight a rare feature in child drug trials
March 19, 2008
Peregrine reports positive cancer data
March 11, 2008
FDA more friendly to approvable than approved
January 10, 2008
Delcath shares hammered on trial enrollment suspension
October 23, 2007
More good news from RNAi company Isis
October 5, 2007
Positive Phase II results for fungal infection drug
October 5, 2007
FDA, Big Pharma collaborate on genetic tests
September 27, 2007
Exelixis garners $71M in public offering
September 13, 2007
Cancer therapy gets accelerated review at Exelixis
August 23, 2007
ViroPharma, Wyeth halt HCV study
August 10, 2007
Press Release: Theravance Announces Positive Results From Phase 2 Clinical Trial
June 26, 2007
Press Release: BMS Reports on First Phase II Short-Term Study of Dapagliflozin
June 25, 2007
BBC: Britain's Largest Drugs Company Faces Accusation of "Fraud"
January 29, 2007
Press Release: Cephalon Announces Positive Results From Two Phase 3 Clinical Trials Of Fentora
January 10, 2007
Press Release: Genentech Announces Positive Results from Phase II Pertuzumab Study
January 5, 2007
Exelixis inks $120M development pact with BMS
December 17, 2006
Press Release: Vertex Pharmaceuticals Announces Results of Investigational HCV Protease Inhibitor Telaprevir
December 12, 2006
Adverse events force delay in Exelixis trial
November 1, 2006
ImClone Chairman Kies out as Icahn gains
October 9, 2006
Critical Therapeutics compound fails in Phase II
September 14, 2006

Paid Research Reports